Divisions of the University of Oxford

Breakthroughs Using AI for Chronic Kidney Disease Monitoring: Vironix Health and Oxford University

Retrieved on: 
Thursday, August 24, 2023
COPD, Kidney disease, University of Oxford, Partnership, University, Peer review, Health care, Research, Mathematical Institute, University of Oxford, Asthma, Student, Science, HIV disease progression rates, Disease, Conceptual model, Chronic kidney disease, CKD, Divisions of the University of Oxford, Medical device, Mathematics, Heart failure

The collaboration aims squarely at advanced prediction of Chronic Kidney Disease (CKD) progression.

Key Points: 
  • The collaboration aims squarely at advanced prediction of Chronic Kidney Disease (CKD) progression.
  • Early interventions leveraging AI can amplify patient well-being, decelerate the disease progression, and reduce healthcare costs.
  • Working with Oxford Mathematics to leverage machine-learning methods for prevention of end-stage renal disease is a timely and critical global effort.
  • To uncover more about Vironix Health Inc.'s expertise in AI-enhanced chronic disease management, visit: https://www.vironix.ai/ .

The Rainwater Charitable Foundation announces partnership with drug discovery teams at the University of Oxford

Retrieved on: 
Thursday, June 2, 2022
K-12, University, Animation, Research, Alzheimer's Research UK, Business, ARUK, Disease, Neurodegeneration, Partnership, Tauopathy, RCF, Divisions of the University of Oxford, Alzheimer's Drug Discovery Foundation, CMD, Therapy, Drug discovery, Computational chemistry, Patient, Nuffield Department of Population Health, ADME, Dementia, United States dollar, Heart, Rain, Center, Pharmaceutical industry, Alzheimer's disease

FORT WORTH, Texas  , June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford. This partnership intends to accelerate the development of novel therapeutics aimed at the treatment of tauopathies, a group of progressive neurodegenerative diseases.

Key Points: 
  • FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford.
  • The deep knowledge in basic discovery biology and tauopathy mechanisms derived from the Tau Consortium principal investigators will complement the drug discovery expertise of the ARUK-ODDI team.
  • The Rainwater Charitable Foundation (RCF) was created in the early 1990s by renowned private equity investor and philanthropist Richard E. Rainwater.
  • The Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) is a research team within the Centre for Medicines Discovery (CMD) at the University of Oxford.

The Rainwater Charitable Foundation announces partnership with drug discovery teams at the University of Oxford

Retrieved on: 
Thursday, June 2, 2022
K-12, University, Animation, Research, Alzheimer's Research UK, Business, ARUK, Disease, Neurodegeneration, Partnership, Tauopathy, RCF, Divisions of the University of Oxford, Alzheimer's Drug Discovery Foundation, CMD, Therapy, Drug discovery, Computational chemistry, Patient, Nuffield Department of Population Health, ADME, Dementia, United States dollar, Heart, Rain, Center, Pharmaceutical industry, Alzheimer's disease

FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford. This partnership intends to accelerate the development of novel therapeutics aimed at the treatment of tauopathies, a group of progressive neurodegenerative diseases.

Key Points: 
  • FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- The Rainwater Charitable Foundation (RCF), one of the largest independent funders of neurodegenerative disease research, today announced that it has entered a partnership with the Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) at the University of Oxford.
  • The deep knowledge in basic discovery biology and tauopathy mechanisms derived from the Tau Consortium principal investigators will complement the drug discovery expertise of the ARUK-ODDI team.
  • The Rainwater Charitable Foundation (RCF) was created in the early 1990s by renowned private equity investor and philanthropist Richard E. Rainwater.
  • The Alzheimer's Research UK Oxford Drug Discovery Institute (ARUK-ODDI) is a research team within the Centre for Medicines Discovery (CMD) at the University of Oxford.

THE BEANS IS NAMED A TOP TECH STARTUP TO WATCH

Retrieved on: 
Tuesday, January 11, 2022
CDC, SAN, United Nations, Social work, Education, Center, CEO, St. Louis Fed Financial Stress Index, Economy, Divisions of the University of Oxford, COVID-19, Lab, First Nations in Ontario, World Health Organization, Behavior, Life, University, Medicine

SAN FRANCISCO, Jan. 11, 2022 /PRNewswire/ -- Tech.co has named financial technology startup, The Beans, to their list of Seven Tech Startups to Watch in 2022 .

Key Points: 
  • SAN FRANCISCO, Jan. 11, 2022 /PRNewswire/ -- Tech.co has named financial technology startup, The Beans, to their list of Seven Tech Startups to Watch in 2022 .
  • The financial wellness company automates monthly cash flow management and keeps members on the right path through proactive behavioral nudges.
  • The Beans aims to improve their financial health by offering a path toward money, life, and balance.
  • This 8-week evidence-based program will help participants establish their essential savings, pay down debt, and break free from financial stress in 2022.

University of Oxford and Oracle Cloud System Helping Researchers Identify COVID-19 Variants Faster

Retrieved on: 
Monday, September 20, 2021
Cloud, Policy, CTO, Delta, SP3, Tony Blair Institute for Global Change, University, Virus, Oracle Corporation, Program, Pathology, Java, Safety, Laboratory, Industry, Southwest Border Security Consortium, Global Health, Old Road Campus, Multimedia, Heart, CEO, Divisions of the University of Oxford, Coronavirus, TBI, Oracle Cloud, Variant of concern, NYSE, Global change, Oxford Nanopore Technologies, Solution, Institute, MySQL, Microbiology, Face, Severe acute respiratory syndrome coronavirus 2, Organization, OCI, Oxford University Innovation, Time, Nuffield Department of Population Health, Oracle Application Express, COVID-19, Public health, View, Research, University of Oxford, Lawrence, Pharmaceutical industry, Vaccine, Medical device, Software

Uniting governments and medical communities in this challenge, the University of Oxford and Oracle's Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent.

Key Points: 
  • Uniting governments and medical communities in this challenge, the University of Oxford and Oracle's Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent.
  • The Global Pathogen Analysis System is being provided as a free resource to help combat COVID-19 and other microbial health threats.
  • Researchers are using the system to upload pathogen data and receive comprehensive results within minutes.
  • Oracle offersintegrated suites of applications plus secure, autonomous infrastructure in the Oracle Cloud.For more information about Oracle (NYSE: ORCL), please visit us at oracle.com .